Congenital hypogonadotropic hypogonadism and Kallmann syndrome as models for studying hormonal regulation of human testicular endocrine functions

Annales d'Endocrinologie

Volumn 75, Issue 2, 2014, Pages 79-87

  Trabado, Séverine ^a,b   Lamothe, Sophie ^c   Maione, Luigi ^c   Bouvattier, Claire ^c   Sarfati, Julie ^c   Brailly Tabard, Sylvie ^a,b   Young, Jacques ^a,c  

^a INSERM   (France)

^b Hop S Louis 1 Ave Claude V   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

AMH; Estradiol; Hypogonadism; Inhibin B; INSL3; Kallmann; Testosterone

Indexed keywords

ESTRADIOL; GONADOTROPIN; INHIBIN B; INSULIN LIKE FACTOR 3; MUELLERIAN INHIBITING FACTOR; PEPTIDE HORMONE; SEX HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG; FOLLITROPIN; HORMONE; INHIBIN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; RECOMBINANT PROTEIN;

ARTICLE; CHRONIC DISEASE; CONGENITAL HYPOGONADOTROPIC HYPOGONADISM; DISEASE SEVERITY; FETUS DEVELOPMENT; GONADOTROPIN DEFICIENCY; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; KALLMANN SYNDROME; LEYDIG CELL; NONHUMAN; PERINATAL PERIOD; SEMINIFEROUS TUBULE; SERTOLI CELL; SIGNAL TRANSDUCTION; TESTIS FUNCTION; UPREGULATION; CONGENITAL MALFORMATION; CRYPTORCHIDISM; DEFICIENCY; DRUG COMBINATION; EMBRYOLOGY; HORMONE SUBSTITUTION; HYPOGONADISM; MALE; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PENIS; PHYSIOLOGY; PUBERTY; SECRETION (PROCESS); TESTIS;

CRYPTORCHIDISM; DRUG THERAPY, COMBINATION; FOLLICLE STIMULATING HORMONE; HORMONE REPLACEMENT THERAPY; HORMONES; HUMANS; HYPOGONADISM; INFANT, NEWBORN; INHIBINS; KALLMANN SYNDROME; LUTEINIZING HORMONE; MALE; PENIS; PUBERTY; RECEPTORS, LH; RECOMBINANT PROTEINS; TESTIS;

EID: 84901271806     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2014.04.011     Document Type: Article

References (102)

1. Young J. Approach to the male patient with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2012, 97:707-718.
2. Brioude F., Bouligand J., Trabado S., Francou B., Salenave S., Kamenicky P., et al. Non-syndromic congenital hypogonadotropic hypogonadism: clinical presentation and genotype-phenotype relationships. Eur J Endocrinol 2010, 162:835-851.
3. Bry-Gauillard H., Trabado S., Bouligand J., Sarfati J., Francou B., Salenave S., et al. Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics. Ann Endocrinol (Paris) 2010, 71:158-162.
4. Bouvattier C., Maione L., Bouligand J., Dodé C., Guiochon-Mantel A., Young J. Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. Nat Rev Endocrinol 2011, 8:172-182.
5. Bouligand J., Ghervan C., Tello J.A., Brailly-Tabard S., Salenave S., Chanson P., et al. Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med 2009, 360:2742-2748.
6. Maione L., Albarel F., Bouchard P., Gallant M., Flanagan C.A., Bobe R., et al. R31C GNRH1 mutation and congenital hypogonadotropic hypogonadism. PLoS One 2013, 8:e69616. 10.1371/journal.pone.
7. Topaloglu A.K., Tello J.A., Kotan L.D., Ozbek M.N., Yilmaz M.B., Erdogan S., et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med 2012, 16(366):629-635.
8. George J.T., Seminara S.B. Kisspeptin and the hypothalamic control of reproduction: lessons from the human. Endocrinology 2012, 153:5130-5136.
9. Brioude F., Bouligand J., Francou B., Fagart J., Roussel R., Viengchareun S., et al. Two families with normosmic congenital hypogonadotropic hypogonadism and biallelic mutations in KISS1R (KISS1 receptor): clinical evaluation and molecular characterization of a novel mutation. PLoS One 2013, 8:e53896.
10. Topaloglu A.K., Reimann F., Guclu M., Yalin A.S., Kotan L.D., Porter K.M., et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the central control of reproduction. Nat Genet 2009, 41:354-358.
11. Young J., Bouligand J., Francou B., Raffin-Sanson M.L., Gaillez S., Jeanpierre M., et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab 2010, 95:2287-2295.
12. Young J., George J.T., Tello J.A., Francou B., Bouligand J., Guiochon-Mantel A., et al. Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications. Neuroendocrinology 2013, 97:193-202.
13. de Roux N., Young J., Misrahi M., Genet R., Chanson P., Schaison G., et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997, 337:1597-1602.
14. Tello J.A., Newton C.L., Bouligand J., Guiochon-Mantel A., Millar R.P., Young J. Congenital hypogonadotropic hypogonadism due to GnRH receptor mutations in three brothers reveal sites affecting conformation and coupling. PLoS One 2012, 7:e38456.
15. Maione L., Benadjaoud S., Eloit C., Sinisi A.A., Colao A., Chanson P., et al. Computed tomography of the anterior skull base in Kallmann syndrome reveals specific ethmoid bone abnormalities associated with olfactory bulb defects. J Clin Endocrinol Metab 2013, 98:E537-E546.
16. Dodé C., Fouveaut C., Mortier G., Janssens S., Bertherat J., Mahoudeau J., et al. Novel FGFR1 sequence variants in Kallmann syndrome, and genetic evidence that the FGFR1c isoform is required in olfactory bulb and palate morphogenesis. Hum Mutat 2007, 28:97-98.
17. Dode C., Hardelin J.P. Clinical genetics of Kallmann syndrome. Ann Endocrinol (Paris) 2010, 71:149-157.
18. Mitchell A.L., Dwyer A., Pitteloud N., Quinton R. Genetic basis and variable phenotypic expression of Kallmann syndrome: towards a unifying theory. Trends Endocrinol Metab 2011, 22:249-258.
19. Teixeira L., Guimiot F., Dodé C., Fallet-Bianco C., Millar R.P., Delezoide A.L., et al. Defective migration of neuroendocrine GnRH cells in human arrhinencephalic conditions. J Clin Invest 2010, 120:3668-3672.
20. Scott H.M., Mason J.I., Sharpe R.M. Steroidogenesis in the fetal testis and its susceptibility to disruption by exogenous compounds. Endocr Rev 2009, 30(7):883-925.
21. O'Shaughnessy P.J., Fowler P.A. Endocrinology of the mammalian fetal testis. Reproduction 2011, 141(1):37-46.
22. Huhtaniemi I., Alevizaki M. Gonadotrophin resistance. Best Pract Res Clin Endocrinol Metab 2006, 20(4):561-576.
23. Latronico A.C., Arnhold I.J. Gonadotropin resistance. Endocr Dev 2013, 24:25-32.
24. Weiss J., Axelrod L., Whitcomb R.W., Harris P.E., Crowley W.F., Jameson J.L. Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. N Engl J Med 1992, 326:179-183.
25. Valdes-Socin H., Salvi R., Daly A.F., Gaillard R.C., Quatresooz P., Tebeu P.M., et al. Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene. N Engl J Med 2004, 351(25):2619-2625.
26. Lofrano-Porto A., Barra G.B., Giacomini L.A., Nascimento P.P., Latronico A.C., Casulari L.A., et al. Luteinizing hormone beta mutation and hypogonadism in men and women. N Engl J Med 2007, 357(9):897-904.
27. Achard C., Courtillot C., Lahuna O., Méduri G., Soufir J.C., Lière P., et al. Normal spermatogenesis in a man with mutant luteinizing hormone. N Engl J Med 2009, 361:1856-1863.
28. Basciani S., Watanabe M., Mariani S., Passeri M., Persichetti A., Fiore D., et al. Hypogonadism in a patient with two novel mutations of the luteinizing hormone β-subunit gene expressed in a compound heterozygous form. J Clin Endocrinol Metab 2012, 97:3031-3038.
29. Maffei L., Rochira V., Zirilli L., Antunez P., Aranda C., Fabre B., et al. A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome. Clin Endocrinol (Oxf) 2007, 67:218-224.
30. Belgorosky A., Guercio G., Pepe C., Saraco N., Rivarola M.A. Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Horm Res 2009, 72:321-330.
31. Bulun S.E. Aromatase and estrogen receptor α deficiency. Fertil Steril 2014, 101:323-329.
32. Young J., Bulun S.E., Agarwal V., Couzinet B., Mendelson C.R., Simpson E.R., et al. Aromatase expression in a feminizing adrenocortical tumor. J Clin Endocrinol Metab 1996, 81:3173-3176.
33. Boukari K., Ciampi M.L., Guiochon-Mantel A., Young J., Lombès M., Meduri G. Human fetal testis: source of estrogen and target of estrogen action. Hum Reprod 2007, 22:1885-1892.
34. Naftolin F., Harris G.W., Bobrow M. Effect of purified luteinizing hormone releasing factor on normal and hypogonadotrophic anosmic men. Nature 1971, 232:496-497.
35. Bougnères P., François M., Pantalone L., Rodrigue D., Bouvattier C., Demesteere E., et al. Effects of an early postnatal treatment of hypogonadotropic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and luteinizing hormone. J Clin Endocrinol Metab 2008, 93:2202-2205.
36. Rey R.A., Grinspon R.P., Gottlieb S., Pasqualini T., Knoblovits P., Aszpis S., et al. Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. Andrology 2013, 1:3-16.
37. Trabado S., Maione L., Bry-Gauillard H., Affres H., Salenave S., Sarfati J., et al. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients. J Clin Endocrinol Metab 2014, 99:E268-E275.
38. Kuhn J.M., Abourachid H., Brucher P., Doutres J.C., Fretin J., Jaupitre A., et al. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur Urol 1997, 32:397-403.
39. Raivio T., Toppari J., Perheentupa A., McNeilly A.S., Dunkel L. Treatment of prepubertal gonadotrophin-deficient boys with recombinant human follicle-stimulating hormone. Lancet 1997, 350:263-264.
40. Young J., Couzinet B., Chanson P., Brailly S., Loumaye E., Schaison G. Effects of human recombinant luteinizing hormone and follicle-stimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions. J Clin Endocrinol Metab 2000, 85:3239-3244.
41. Young J., Chanson P., Salenave S., Noël M., Brailly S., O'Flaherty M., et al. Testicular anti-Mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005, 90:724-728.
42. Raivio T., Wikström A.M., Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur J Endocrinol 2007, 156:105-111.
43. Trabado S., Maione L., Salenave S., Baron S., Galland F., Bry-Gauillard H., et al. Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects of different modalities of hormonal treatment. Fertil Steril 2011, 95:2324-2329. 2329.e1-3.
44. Dwyer A.A., Sykiotis G.P., Hayes F.J., Boepple P.A., Lee H., Loughlin K.R., et al. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2013, 98:E1790-E1795.
45. Tapanainen J.S., Aittomäki K., Min J., Vaskivuo T., Huhtaniemi I.T. Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. Nat Genet 1997, 15:205-206.
46. Matthews C.H., Borgato S., Beck-Peccoz P., Adams M., Tone Y., Gambino G., et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet 1993, 5:83-86.
47. Kottler M.L., Chou Y.Y., Chabre O., Richard N., Polge C., Brailly-Tabard S., et al. A new FSHbeta mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. Eur J Endocrinol 2010, 162:633-641.
48. Lindstedt G., Nyström E., Matthews C., Ernest I., Janson P.O., Chatterjee K. Follitropin (FSH) deficiency in an infertile male due to FSH beta gene mutation. A syndrome of normal puberty and virilization but underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. Clin Chem Lab Med 1998, 36:663-665.
49. Layman L.C., Porto A.L., Xie J., da Motta L.A., da Motta L.D., Weiser W., et al. FSH beta gene mutations in a female with partial breast development and a male sibling with normal puberty and azoospermia. J Clin Endocrinol Metab 2002, 87:3702-3707.
50. Phillip M., Arbelle J.E., Segev Y., Parvari R. Male hypogonadism due to a mutation in the gene for the beta-subunit of follicle-stimulating hormone. N Engl J Med 1998, 338:1729-1732.
51. Winters S.J., Troen P. Testosterone and estradiol are co-secreted episodically by the human testis. J Clin Invest 1986, 78:870-873.
52. Skinner M.K. Cell-cell interactions in the testis. Endocr Rev 1991, 12:45-77.
53. Lejeune H., Sanchez P., Saez J.M. Enhancement of long-term testosterone secretion and steroidogenic enzyme expression in human Leydig cells by co-culture with human Sertoli cell-enriched preparations. Int J Androl 1998, 21:129-140.
54. Khosla S., Amin S., Orwoll E. Osteoporosis in men. Endocr Rev 2008, 29:441-464.
55. Finkelstein J.S., Klibanski A., Neer R.M., Greenspan S.L., Rosenthal D.I., Crowley W.F. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987, 106:354-361.
56. Finkelstein J.S., Klibanski A., Neer R.M., Doppelt S.H., Rosenthal D.I., Segre G.V., et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989, 69:776-783.
57. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997, 82:2386-2390.
58. Finkelstein J.S., Whitcomb R.W., O'Dea L.S., Longcope C., Schoenfeld D.A., Crowley W.F. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 1991, 73:609-620.
59. Brodie A., Inkster S., Yue W. Aromatase expression in the human male. Mol Cell Endocrinol 2001, 178:23-28.
60. Winters J.S., Huhgues I.A., Reyes F.I., Faiman C. Pituitary-gonadal relations in infancy: 2. Patterns of serum gonadal steroid concentrations in man from birth to two years of age. J Clin Endocrinol Metab 1976, 42:679-686.
61. Bidlingmaier F., Strom T.M., Dörr H.G., Eisenmenger W., Knorr D. Estrone and estradiol concentrations in human ovaries, testes, and adrenals during the first two years of life. J Clin Endocrinol Metab 1987, 65:862-867.
62. Berensztein E.B., Baquedano M.S., Gonzalez C.R., Saraco N.I., Rodriguez J., Ponzio R., et al. Expression of aromatase, estrogen receptor alpha and beta, androgen receptor, and cytochrome P-450scc in the human early prepubertal testis. Pediatr Res 2006, 60:740-744.
63. Ferlin A., Foresta C. Insulin-like factor 3: a novel circulating hormone of testicular origin in humans. Ann N Y Acad Sci 2005, 1041:497-505.
64. Foresta C., Zuccarello D., Garolla A., Ferlin A. Role of hormones, genes, and environment in human cryptorchidism. Endocr Rev 2008, 29:560-580.
65. Ivell R., Anand-Ivell R. Biology of insulin-like factor 3 in human reproduction. Hum Reprod Update 2009, 15:463-476.
66. Bay K., Main K.M., Toppari J., Skakkebæk N.E. Testicular descent: INSL3, testosterone, genes and the intrauterine milieu. Nat Rev Urol 2011, 8:187-196.
67. Nef S., Parada L.F. Cryptorchidism in mice mutant for Insl3. Nat Genet 1999, 22:295-299.
68. Zimmermann S., Steding G., Emmen J.M., Brinkmann A.O., Nayernia K., Holstein A.F., et al. Targeted disruption of the Insl3 gene causes bilateral cryptorchidism. Mol Endocrinol 1999, 13:681-691.
69. Overbeek P.A., Gorlov I.P., Sutherland R.W., Houston J.B., Harrison W.R., Boettger-Tong H.L., et al. A transgenic insertion causing cryptorchidism in mice. Genesis 2001, 30:26-35.
70. Bay K., Virtanen H.E., Hartung S., Ivell R., Main K.M., Skakkebaek N.E., et al. Insulin-like factor 3 levels in cord blood and serum from children: effects of age, postnatal hypothalamic-pituitary-gonadal axis activation, and cryptorchidism. J Clin Endocrinol Metab 2007, 92:4020-4027.
71. Ferlin A., Garolla A., Rigon F., Rasi Caldogno L., Lenzi A., Foresta C. Changes in serum insulin-like factor 3 during normal male puberty. J Clin Endocrinol Metab 2006, 91:3426-3431.
72. Johansen M.L., Anand-Ivell R., Mouritsen A., Hagen C.P., Mieritz M.G., Søeborg T., et al. Serum levels of insulin-like factor 3, anti-Mullerian hormone, inhibin B, and testosterone during pubertal transition in healthy boys: a longitudinal pilot study. Reproduction 2014, 147:529-535.
73. Bay K., Hartung S., Ivell R., Schumacher M., Jü rgensen D., Jorgensen N., et al. Insulin-like factor 3 serum levels in 135 normal men and 85 men with testicular disorders: relationship to the luteinizing hormone-testosterone axis. J Clin Endocrinol Metab 2005, 90:3410-3418.
74. Foresta C., Bettella A., Vinanzi C., Dabrilli P., Meriggiola M.C., Garolla A., et al. Insulin-like factor 3, a novel circulating hormone of testis origin in humans. J Clin Endocrinol Metab 2004, 89:5952-5958.
75. Bay K., Matthiesson K.L., McLachlan R.I., Andersson A.M. The effects of gonadotropin suppression and selective replacement on insulin-like factor 3 secretion in normal adult men. J Clin Endocrinol Metab 2006, 91:1108-1111.
76. Ivell R., Heng K., Anand-Ivell R. Insulin-like factor 3 and the HPG axis in the male. Front Endocrinol (Lausanne) 2014, 5:6. eCollection 2014.
77. Illingworth P.J., Groome N.P., Byrd W., Rainey W.E., McNeilly A.S., Mather J.P., et al. Inhibin-B: a likely candidate for the physiologically important form of inhibin in men. J Clin Endocrinol Metab 1996, 81:1321-1325.
78. Walton K.L., Makanji Y., Robertson D.M., Harrison C.A. The synthesis and secretion of inhibins. Vitam Horm 2011, 85:149-184.
79. Anawalt B.D., Bebb R.A., Matsumoto A.M., Groome N.P., Illingworth P.J., McNeilly A.S., et al. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 1996, 81:3341-3345.
80. Debieve F., Beerlandt S., Hubinont C., Thomas K. Gonadotropins, prolactin, inhibin A, inhibin B, and activin A in human fetal serum from midpregnancy and term pregnancy. J Clin Endocrinol Metab 2000, 85:270-274.
81. Crofton P.M., Evans A.E., Groome N.P., Taylor M.R., Holland C.V., Kelnar C.J. Inhibin B in boys from birth to adulthood: relationship with age, pubertal stage, FSH and testosterone. Clin Endocrinol (Oxf) 2002, 56:215-221.
82. Christiansen P., Andersson A.M., Skakkebaek N.E. Longitudinal studies of inhibin B levels in boys and young adults with Klinefelter syndrome. J Clin Endocrinol Metab 2003, 88:888-891.
83. Andersson A.M., Müller J., Skakkebaek N.E. Different roles of prepubertal and postpubertal germ cells and Sertoli cells in the regulation of serum inhibin B levels. J Clin Endocrinol Metab 1998, 83:4451-4458.
84. Fujisawa M., Yamazaki T., Fujioka H., Takenaka A. Differential regulation of inhibin subunits by germ cells in human testes. Arch Androl 2004, 50:339-345.
85. Marchetti C., Hamdane M., Mitchell V., Mayo K., Devisme L., Rigot J.M., et al. Immunolocalization of inhibin and activin alpha and betaB subunits and expression of corresponding messenger RNAs in the human adult testis. Biol Reprod 2003, 68:230-235.
86. Bergada I., Milani C., Bedecarras P., Andreone L., Ropelato M.G., Gottlieb S., et al. Time course of the serum gonadotropin surge, inhibins, and anti-Mullerian hormone in normal newborn males during the first month of life. J Clin Endocrinol Metab 2006, 91:4092-4098.
87. Plant T.M., Padmanabhan V., Ramaswamy S., McConnell D.S., Winters S.J., Groome N., et al. Circulating concentrations of dimeric inhibin A and B in the male rhesus monkey (Macaca mulatta). J Clin Endocrinol Metab 1997, 82:2617-2621.
88. Nieschlag E., Zitzmann M., Kamischke A. Use of progestins in male contraception. Steroids 2003, 68:965-972.
89. Nachtigall L.B., Boepple P.A., Seminara S.B., Khoury R.H., Sluss P.M., Lecain A.E., et al. Inhibin B secretion in males with gonadotropin-releasing hormone (GnRH) deficiency before and during long-term GnRH replacement: relationship to spontaneous puberty, testicular volume, and prior treatment - a clinical research center study. J Clin Endocrinol Metab 1996, 81:3520-3525.
90. Seminara S.B., Boepple P.A., Nachtigall L.B., Pralong F.P., Khoury R.H., Sluss P.M., et al. Inhibin B in males with gonadotropin-releasing hormone (GnRH) deficiency: changes in serum concentration after short-term physiologic GnRH replacement - a clinical research center study. J Clin Endocrinol Metab 1996, 81:3692-3696.
91. Pitteloud N., Hayes F.J., Boepple P.A., DeCruz S., Seminara S.B., MacLaughlin D.T., et al. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002, 87:152-160.
92. Dwyer A.A., Hayes F.J., Plummer L., Pitteloud N., Crowley W.F. The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2010, 95:4235-4243.
93. Lofrano-Porto A., Casulari L.A., Nascimento P.P., Giacomini L., Naves L.A., da Motta L.D., et al. Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone beta subunit mutation. Fertil Steril 2008, 90:1169-1174.
94. Libe R., Fratticci A., Lahlou N., Jornayvaz F.R., Tissier F., Louiset E., et al. A rare cause of hypertestosteronemia in a 68-year-old patient: a Leydig cell tumor due to a somatic GNAS (Guanine Nucleotide-Binding Protein, Alpha-Stimulating Activity Popylpetide 1)-activating mutation. J Androl 2012, 33:578-584.
95. Coutant R., Lumbroso S., Rey R., Lahlou N., Venara M., Rouleau S., et al. Macroorchidism due to autonomous hyperfunction of Sertoli cells and Gsα gene mutation: an unusual expression of McCune-Albright syndrome in a prepubertal boy. J Clin Endocrinol Metab 2001, 86:1778-1781.
96. Josso N., Picard J.Y., Rey R., Clemente N. Testicular anti-Mullerian hormone: history, genetics, regulation and clinical applications. Pediatr Endocrinol Rev 2006, 3:347-358.
97. Chemes H.E., Rey R.A., Nistal M., Regadera J., Musse M., Gonzalez-Peramato P., et al. Physiologic androgen insensitivity of the foetal, neonatal, and early infantile testis is explained by the ontogeny of the androgen receptor expression in Sertoli cells. J Clin Endocrinol Metab 2008, 93:4408-4412.
98. Boukari K., Meduri G., Brailly-Tabard S., Guibourdenche J., Ciampi M.L., Massin N., et al. Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development. J Clin Endocrinol Metab 2009, 94:1818-1825.
99. Guibourdenche J., Lucidarme N., Chevenne D., Rigal O., Nicolas M., Luton D., et al. Anti-Mullerian hormone levels in serum from human foetuses and children: pattern and clinical interest. Mol Cell Endocrinol 2003, 211:55-63.
100. Cortes D., Müller J., Skakkebaek N.E. Proliferation of Sertoli cells during development of the human testis assessed by stereological methods. Int J Androl 1987, 10:589-596.
101. Lukas-Croisier C., Lasala C., Nicaud J., Bedecarras P., Kumar T.R., Dutertre M., et al. Follicle-stimulating hormone increases testicular anti-Mullerian hormone (AMH) production through Sertoli cell proliferation and a nonclassical cyclic adenosine 5_-monophosphatemediated activation of the AMH gene. Mol Endocrinol 2003, 17:550-561.
102. Rey R., Lordereau-Richard I., Carel J.C., Barbet P., Cate R.L., Roger M., et al. Anti-mullerian hormone and testosterone serum levels are inversely related during normal and precocious pubertal development. J Clin Endocrinol Metab 1993, 77:1220-1226.